Prospective study of Lisocabtagene Maraleucel and Idecabtagene Vicleucel therapy in in refractory diffuse large B-cell lymphoma and multiple myeloma
Latest Information Update: 17 Jan 2023
At a glance
- Drugs Idecabtagene vicleucel (Primary) ; Lisocabtagene-maraleucel (Primary)
- Indications Diffuse large B cell lymphoma; Multiple myeloma
- Focus Therapeutic Use
- 17 Jan 2023 New trial record
- 13 Dec 2022 Results (n=20; Between September 2021 and March 2022) presented at the 64th American Society of Hematology Annual Meeting and Exposition.